

**DESCRIPTION**

<b>Source</b>	Chinese Hamster Ovary cell line, CHO-derived			
	Mouse Integrin $\alpha 5$ Phe45-Asn999 (Gly377Ala) Accession # P11688	GS Linker	Acidic Tail	HHHHHH
	Mouse Integrin $\beta 1$ (Gln21-Asp728) Accession # P09055	HP	GS Linker	Basic Tail
	N-terminus			C-terminus

**N-terminal Sequence** Phe45 (Integrin  $\alpha 5$ ) & Gln21 predicted, No results obtained: sequencing might be blocked (Integrin  $\beta 1$ )

**Analysis**

**Structure / Form** Noncovalently-linked heterodimer

**Predicted Molecular Mass** 113 kDa (Integrin  $\alpha 5$ ) & 86.5 kDa (Integrin  $\beta 1$ )

**SPECIFICATIONS**

**SDS-PAGE** 115-165 kDa, reducing conditions

**Activity** Measured by its binding ability in a functional ELISA.  
When Bovine Fibronectin (Catalog # 1030-FN) is coated at 2  $\mu\text{g}/\text{mL}$ , Recombinant Mouse Integrin  $\alpha 5\beta 1$  binds with an apparent  $K_D < 0.5 \text{ nM}$ .

**Endotoxin Level**  $< 0.10 \text{ EU per } 1 \mu\text{g}$  of the protein by the LAL method.

**Purity**  $> 95\%$ , by SDS-PAGE under reducing conditions and visualized by silver stain.

**Formulation** Lyophilized from a 0.2  $\mu\text{m}$  filtered solution in PBS. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

**Reconstitution** Reconstitute at 500  $\mu\text{g}/\text{mL}$  in PBS.

**Shipping** The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt,  $-20$  to  $-70 \text{ }^\circ\text{C}$  as supplied.
- 1 month, 2 to 8  $^\circ\text{C}$  under sterile conditions after reconstitution.
- 3 months,  $-20$  to  $-70 \text{ }^\circ\text{C}$  under sterile conditions after reconstitution.

**BACKGROUND**

Integrin alpha 5 beta 1, also known as VLA-5, is a widely expressed non-covalent heterodimer of a 160 kDa  $\alpha 5$  and a 130 kDa  $\beta 1$  Integrin subunit.  $\alpha 5/\beta 1$  functions in cell adhesion, migration, activation, and matrix fibrillogenesis (1, 2). Mature mouse Integrin  $\alpha 5/\text{CD}49\text{e}$  consists of a 955 aa extracellular domain (ECD) with 7 tandem FG-GAP repeats, a 26 aa transmembrane segment, and a 28 aa cytoplasmic domain (3). Within the ECD, mouse  $\alpha 5$  shares 91% and 97% aa sequence identity with human and rat  $\alpha 5$ , respectively. Mature mouse Integrin  $\beta 1/\text{CD}29$  consists of a 708 aa ECD with one vWF-A domain and a cysteine-rich region, followed by a 23 aa transmembrane segment and a 47 aa cytoplasmic domain (3). Within the ECD, mouse  $\beta 1$  shares 93% and 98% aa sequence identity with human and rat  $\beta 1$ , respectively.  $\alpha 5/\beta 1$  binds Fibronectin in both RGD-dependent and -independent manners (4, 5). It is up-regulated on tumor vasculature and promotes angiogenesis (6, 7). This is accomplished in part by a constitutive association *in cis* of  $\alpha 5/\beta 1$  with VEGF R3 and Tie-2, a requirement for optimal activation of those receptors (8, 9).  $\alpha 5/\beta 1$  interacts with a variety of other proteins, including ErbB2, uPAR, Galectin-1, CTGF, and thrombin-cleaved Osteopontin (5, 10-13).  $\alpha 5/\beta 1$  also functions on some hematopoietic and neuronal stem cells (14-16).

**References:**

1. Mao, Y. and Schwarzbauer, J.E. (2005) Matrix Biol. **24**:389.
2. Gu, J. and Taniguchi, N. (2004) Glycoconj. J. **21**:9.
3. Holers, V.M. *et al.* (1989) J. Exp. Med. **169**:1589.
4. Takagi, J. *et al.* (2003) EMBO J. **22**:4607.
5. Wei, Y. *et al.* (2005) J. Cell Biol. **168**:501.
6. Parsons-Wingenter, P. *et al.* (2005) Am. J. Pathol. **167**:193.
7. Kim, S. *et al.* (2000) Am. J. Pathol. **156**:1345.
8. Zhang, X. *et al.* (2004) J. Cell. Physiol. **202**:205.
9. Cascone, I. *et al.* (2005) J. Cell Biol. **170**:993.
10. Kuwada, S.K. *et al.* (2005) J. Biol. Chem. **280**:19027.
11. Fischer, C. *et al.* (2005) J. Biol. Chem. **280**:37266.
12. Gao, R. and Brigstock, D.R. (2005) Gastroenterology **129**:1019.
13. Yokosaki, Y. *et al.* (2005) Matrix Biol. **24**:418.
14. Carstanjen, D. *et al.* (2005) Transfusion **45**:1192.
15. Gibson, R.M. *et al.* (2005) Mol. Cell. Neurosci. **28**:588.
16. Tanaka, R. *et al.* (2009) J. Biol. Chem. **284**:19817.